Register Login
Register to leave comments
  • News bot Jan. 30, 2026, 8:16 a.m.

    📋 Wave Life Sciences (WVE) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:35:22

    Event Type: Clinical Trial Update

    Event Details:

    Wave Life Sciences (WVE) Announces Clinical Trial Update Wave Life Sciences (WVE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: potential, disease
    • Diseases/Conditions: once or twice-yearly dosing
    • Clinical Stage: clinical trial
    • Collaboration: CTA
    • Updated Timeline: December 31, 2025
      • targeting modalities includes RNAi, editing, splicing, and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, timing, design, dosing regimen, safety profile, progress, data and announcements related to our clinical trials, including interactions with and feedback from regulators and any potential registrational submissions based on these data; the future performance and results of our programs in clinical trials, including the anticipated therapeutic benefits of such programs and our expectations with respect to how our clinical data may predict success for our future therapeutic candidates and data readouts; the anticipated status and progress of our programs relative to potential competitors and how our programs differ from competitors’ programs; the potential commercialization of our programs the patient population estimates of the markets that our therapeutics may address; preclinical activities and programs and their potential to transition into clinical-stage programs, and the timing, progress and announcement of such events; the progress and potential benefits, including the potential achievement of milestones, of collaborations and strategic partnerships; the expected benefits of our stereopure oligonucleotides compared with stereorandom oligonucleotides; the breadth and versatility of our PRISM® drug discovery and development platform; the potential benefits of our RNAi and RNA editing capabilities, including our AIMers; our potential to innovate a new bifunctional modality and the anticipated therapeutics benefits of such modality; the potential benefits of our Stereopure interfering Nucleic Acid (SpiNA) next generation siRNA design; the potential for certain of our programs to be best-in-class or first-in-class, or to change the existing treatment paradigm or show substantial benefits over existing standards of care; our financial performance, including the anticipated duration of our cash runway and our ability to fund future operations; our preliminary, unaudited cash and cash equivalents as of December 31, 2025
      • anticipated initiation, timing, design, dosing regimen, safety profile, progress, data and announcements related to our clinical trials, including interactions with and feedback from regulators and any potential registrational submissions based on these data; the future performance and results of our programs in clinical trials, including the anticipated therapeutic benefits of such programs and our expectations with respect to how our clinical data may predict success for our future therapeutic candidates and data readouts; the anticipated status and progress of our programs relative to potential competitors and how our programs differ from competitors’ programs; the potential commercialization of our programs the patient population estimates of the markets that our therapeutics may address; preclinical activities and programs and their potential to transition into clinical-stage programs, and the timing, progress and announcement of such events; the progress and potential benefits, including the potential achievement of milestones, of collaborations and strategic partnerships; the expected benefits of our stereopure oligonucleotides compared with stereorandom oligonucleotides; the breadth and versatility of our PRISM® drug discovery and development platform; the potential benefits of our RNAi and RNA editing capabilities, including our AIMers; our potential to innovate a new bifunctional modality and the anticipated therapeutics benefits of such modality; the potential benefits of our Stereopure interfering Nucleic Acid (SpiNA) next generation siRNA design; the potential for certain of our programs to be best-in-class or first-in-class, or to change the existing treatment paradigm or show substantial benefits over existing standards of care; our financial performance, including the anticipated duration of our cash runway and our ability to fund future operations; our preliminary, unaudited cash and cash equivalents as of December 31, 2025
      • expected in 2026

    🔬 Clinical Development Pipeline (Wave Life Sciences):

    Product Type Development Stage Therapeutic Area Source
    WVE-N531 DRUG Phase PHASE1 Duchenne Muscular Dystrophy ClinicalTrials.gov
    WVE-007 DRUG Phase PHASE1 Obesity and Overweight ClinicalTrials.gov
    WVE-006 DRUG Phase PHASE1 Alpha-1 Antitrypsin Deficiency ClinicalTrials.gov
    18 F fluorodeoxyglucose RADIATION Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov
    Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose) RADIATION Phase PHASE2 Non Small Cell Lung Cancer ClinicalTrials.gov
    Technetium 99m ethylenedicysteine-deoxyglucose RADIATION Phase PHASE1 Non Small Cell Lung Cancer ClinicalTrials.gov
    Dual antiplatelet therapy DRUG Approved Coronary Artery Disease ClinicalTrials.gov
    Percutaneous coronary intervention DEVICE Approved Coronary Artery Disease ClinicalTrials.gov
    Oralair DRUG Preclinical Allergy ClinicalTrials.gov
    rAAV2/5-hNAGLU DRUG Phase PHASE1 Sanfilippo Syndrome B ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Duchenne Muscular Dystrophy ClinicalTrials.gov
    WVE-210201 DRUG Phase PHASE1 Duchenne Muscular Dystrophy ClinicalTrials.gov
    GYNODAKTARIN® DRUG Phase PHASE3 Vaginitis ClinicalTrials.gov
    POLYGYNAX® DRUG Phase PHASE3 Vaginitis ClinicalTrials.gov
    BDM-2 in Bottle (50 mg - 3600 mg); oral suspension DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    WVE-210201 (suvodirsen) DRUG Phase PHASE2 Duchenne Muscular Dystrophy ClinicalTrials.gov
    WVE-120101 DRUG Phase PHASE1 Huntington Disease ClinicalTrials.gov
    WVE-120102 DRUG Phase PHASE1 Huntington Disease ClinicalTrials.gov
    Placebo ALZT-OP1b OTHER Phase PHASE3 Alzheimer's Disease ClinicalTrials.gov
    Placebo ALZT-OP1a OTHER Phase PHASE3 Alzheimer's Disease ClinicalTrials.gov
    ALZT-OP1b DRUG Phase PHASE3 Alzheimer's Disease ClinicalTrials.gov
    ALZT-OP1a DRUG Phase PHASE3 Alzheimer's Disease ClinicalTrials.gov
    Ceftobiprole medocaril DRUG Preclinical Renal Insufficiency ClinicalTrials.gov
    WVE-004 DRUG Phase PHASE1 ALS ClinicalTrials.gov
    MD: Placebo DRUG Phase PHASE1 Huntington Disease ClinicalTrials.gov
    MD: 30mg WVE-003 DRUG Phase PHASE1 Huntington Disease ClinicalTrials.gov
    SAD: Pooled Placebo DRUG Phase PHASE1 Huntington Disease ClinicalTrials.gov
    SAD: 90mg WVE-003 DRUG Phase PHASE1 Huntington Disease ClinicalTrials.gov
    SAD: 60mg WVE-003 DRUG Phase PHASE1 Huntington Disease ClinicalTrials.gov
    SAD: 30mg WVE-003 DRUG Phase PHASE1 Huntington Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Wave Life Sciences
    • Ticker Symbol: WVE

Search

News categories